Targets › GNRHR
78 programs from 63 companies in 132 trials: 68 Phase 2, 36 Phase 3, 18 Phase 4, 10 Phase 1; Oncology, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.
Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P30968)
Open in Phaseline: the race on GNRHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Turku University Hospital | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 4 | Prostatic Hyperplasia; Localized Prostate Carcinoma | Dec 2026 |
| Li-jun Ding | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | Deep Infiltrating Endometriosis (DIE) | Dec 2026 |
| Aristotle University Of Thessaloniki | Goserelin Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Apr 2027 |
| University Reproductive Associates | Gonadorelin Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | Infertility | Jul 2027 |
| University of Delaware | ganirelix acetate GnRH receptor antagonist | GNRHR | Phase 4 | Estrogen | Oct 2027 |
| HanAll BioPharma | Leuprolide Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | CPP | Nov 2027 |
| Fundacion Dexeus | Intranasal nafarelin GnRH receptor agonist | GNRHR | Phase 4 | Fertility Preservation | Jan 2028 |
| University of Colorado, Denver | Degarelix Acetate Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 4 | Menopause | May 2028 |
| LG Chem | Leuprolide Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | Central Precocious Puberty; Prostate Cancer; Androgen Deprivation Therapy; Advanced Salivary Gland Carcinoma … | Aug 2029 |
| Gangnam Severance Hospital | Goserelin acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | Breast Cancer | Jan 2031 |
| Gangnam Severance Hospital | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | Breast Cancer | Jan 2031 |
| Qilu Pharmaceutical | Relugolix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Heavy Menstrual Bleeding; Cervical Mucus; Endometriosis; Recurrent Prostate Carcinoma … | Nov 2026 |
| Ottawa Hospital Research Institute | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Prostate Cancer | Nov 2026 |
| Fundación para la Investigación del Hospital Clínico de Valencia | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Low Ovarian Reserve | Jul 2027 |
| AbbVie | Elagolix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Endometriosis; Menopause; Infertility | Jul 2027 |
| Pfizer | Leuprolide Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Hormone Sensitive Prostate Cancer | Jul 2027 |
| UNICANCER | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Metastases | Sep 2027 |
| Assistance Publique - Hôpitaux de Paris | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | In Vitro Fertilization | Sep 2027 |
| Kissei Pharmaceutical | Linzagolix (KLH-2109) Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Endometriosis | Nov 2027 |
| Proton Collaborative Group | buserelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Prostate Cancer | Dec 2027 |
| Proton Collaborative Group | triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Prostate Cancer | Dec 2027 |
| Kenny Rodriguez-Wallberg | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Breast Cancer Female | Jan 2028 |
| JW Pharmaceutical | Linzagolix (KLH-2109) Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Menorrhagia | Mar 2028 |
| Sumitomo Pharma Switzerland | Relugolix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Uterine Fibroids | Jul 2029 |
| Children's Oncology Group | Triptorelin Pamoate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Hematopoietic and Lymphatic System Neoplasm | Oct 2029 |
| Marco Lorenzo Bonu | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Prostate Cancer | Dec 2029 |
| Alliance for Clinical Trials in Oncology | goserelin acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Prostate Cancer | Oct 2030 |
| Alliance for Clinical Trials in Oncology | leuprolide acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Prostate Cancer | Oct 2030 |
| Radiation Therapy Oncology Group | Luteinizing hormone-releasing hormone (LHRH) agonist or antagonist LHRH receptor agonist or antagonist - suppresses testosterone production | GNRHR | Phase 3 | Prostate Cancer | Jul 2031 |
| NRG Oncology | GnRH agonist GnRH receptor agonist - suppresses ovarian function | GNRHR | Phase 3 | Breast Cancer | Jan 2032 |
| Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Prostate Cancer | Dec 2032 |
| SWOG Cancer Research Network | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Castration Levels of Testosterone | Apr 2033 |
| European Organisation for Research and Treatment of Cancer - EORTC | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Prostate Cancer | – |
| Changchun GeneScience Pharmaceutical | Leuprolide Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Breast Cancer Subjects | – |
| The University of Hong Kong | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Subfertility | – |
| Rumah Sakit Pusat Angkatan Darat Gatot Soebroto | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Endometriosis | – |
| National Cancer Institute (NCI) | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Locally Advanced Salivary Gland Carcinoma | Nov 2026 |
| National Taiwan University Hospital | Goserelin Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Triple Negative Breast Cancer | Dec 2026 |
| Fudan University | LHRH agonist or antagonist Luteinizing hormone-releasing hormone receptor agonist/antagonist | GNRHR | Phase 2 | Metastatic Prostate Cancer | Dec 2026 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostate Cancer | Dec 2026 |
| National Taiwan University Hospital | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Triple Negative Breast Cancer | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | Leuprolide acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Leukemia; Prostate Cancer | Dec 2026 |
| SOLTI Breast Cancer Research Group | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Breast Cancer | Dec 2026 |
| National Taiwan University Hospital | Triptorelin pamoate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Triple Negative Breast Cancer | Dec 2026 |
| Jonsson Comprehensive Cancer Center | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Metastatic Prostate Adenocarcinoma | Jan 2027 |
| City of Hope Medical Center | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Prostate Adenocarcinoma | Jan 2027 |
| City of Hope Medical Center | Goserelin Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostate Adenocarcinoma; PSA Level Greater Than Two | Jan 2027 |
| City of Hope Medical Center | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostate Adenocarcinoma; PSA Level Greater Than Two | Jan 2027 |
| Regina Elena Cancer Institute | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostate Cancer | Feb 2027 |
| Bedaya Hospital | Cetrorelix acetate Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Infertility | Mar 2027 |
| Fudan University | Triprorelin Acetate Gonadotropin-releasing hormone agonist (GnRHa) | GNRHR | Phase 2 | Endometrial Neoplasm Malignant Stage I | Mar 2027 |
| Jose Pablo Leone | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Male Breast Cancer | Apr 2027 |
| Sir Mortimer B. Davis - Jewish General Hospital | Goserelin Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Castration-resistant Prostate Cancer Patients with Oligometastases | Apr 2027 |
| Sir Mortimer B. Davis - Jewish General Hospital | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Castration-resistant Prostate Cancer Patients with Oligometastases | Apr 2027 |
| Sir Mortimer B. Davis - Jewish General Hospital | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Castration-resistant Prostate Cancer Patients with Oligometastases | Apr 2027 |
| Ottawa Hospital Research Institute | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostatic Neoplasms | Jun 2027 |
| Martin Blomberg Jensen | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Menopausal Osteoporosis | Dec 2027 |
| Fudan University | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Endometrial Cancer | Dec 2027 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostate Cancer Metastatic Disease | Dec 2027 |
| Xiaojun Chen | GnRHa (Triprorelin acetate) Gonadotropin-releasing hormone analogue | GNRHR | Phase 2 | Endometrial Neoplasms | Mar 2028 |
| NYU Langone Health | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Prostate Cancer | Aug 2028 |
| Nelly Pitteloud | GnRH, gonadorelin acetate GnRH receptor agonist; pulsatile GnRH acts on GNRHR in the pituitary gland to stimulate LH | GNRHR | Phase 2 | Down Syndrome | Dec 2028 |
| Mayo Clinic | Goserelin Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Anatomic Stage I Breast Cancer AJCC v8 | Dec 2028 |
| Seoul National University Hospital | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Breast Cancer | Dec 2028 |
| VA Office of Research and Development | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Prostate Cancer | Mar 2029 |
| Memorial Sloan Kettering Cancer Center | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Prostate Cancer | Jan 2030 |
| Baptist Health South Florida | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Prostate Cancer | Feb 2030 |
| Baptist Health South Florida | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostate Cancer | Feb 2030 |
| Universitaire Ziekenhuizen KU Leuven | Triptoreline GnRH receptor agonist (androgen deprivation therapy) | GNRHR | Phase 2 | Prostate Cancer | Feb 2031 |
| Ontario Clinical Oncology Group (OCOG) | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Prostate Adenocarcinoma | Apr 2031 |
| UNICANCER | Degarelix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 2 | Adenocarcinoma of Prostate | – |
| Hopital Foch | Triptorelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 2 | Endometriosis | – |
| Amgen | GnRH Antagonist Gonadotropin-releasing hormone antagonist | GNRHR | Phase 1 | Prostate Cancer; Atypical Endometrial Hyperplasia; Endometrial Neoplasms | Feb 2027 |
| TerSera Therapeutics | Goserelin Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 1 | Advanced Breast Cancer; Musculoskeletal Injury; Prostate Cancer; Breast Cancer … | Mar 2027 |
| Zhuhai Huahaikang Pharmaceutical Technology | HHK001 GnRH receptor agonist (leuprorelin acetate) | GNRHR | Phase 1 | Endometriosis | Mar 2027 |
| Roswell Park Cancer Institute | Leuprolide Acetate Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 1 | Castration-Resistant Prostate Carcinoma | Mar 2028 |
| Peter Busch Østergren | ADT (gonadotropin-releasing hormone antagonist or agonist) Gonadotropin-releasing hormone antagonist or agonist for medical castration | GNRHR | Phase 1 | Prostate Cancer Metastatic | Oct 2028 |
| The Affiliated Hospital of Qingdao University | Triprorelin for injection GnRH receptor agonist | GNRHR | Phase 1 | Prostate Cancer (CRPC) | – |
Prostate Cancer (39) Prostate Adenocarcinoma (7) Endometriosis (7) Breast Cancer (7) Menopause (4) Anatomic Stage I Breast Cancer AJCC v8 (3) Infertility (3) Castration-resistant Prostate Cancer Patients with Oligometastases (3) Triple Negative Breast Cancer (3) Androgen Deprivation Therapy (2) Tubular Breast Cancer (2) PSA Level Greater Than Two (2)
small molecule (71), mixed (4), protein or peptide (2)
Fudan University (3) City of Hope Medical Center (3) Sir Mortimer B. Davis - Jewish General Hospital (3) National Taiwan University Hospital (3) UNICANCER (2) Baptist Health South Florida (2) Proton Collaborative Group (2) Memorial Sloan Kettering Cancer Center (2) Ottawa Hospital Research Institute (2) Gangnam Severance Hospital (2) Alliance for Clinical Trials in Oncology (2) LG Chem (1) Assistance Publique - Hôpitaux de Paris (1) Universitaire Ziekenhuizen KU Leuven (1) JW Pharmaceutical (1) The University of Hong Kong (1) Martin Blomberg Jensen (1) European Organisation for Research and Treatment of Cancer - EORTC (1) Rumah Sakit Pusat Angkatan Darat Gatot Soebroto (1) SOLTI Breast Cancer Research Group (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.